VFA
ALXN

Virtus Fund Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Virtus Fund Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$8.23M Buy
68,801
+6,608
+11% +$805K 0.08% 197
2017
Q3 		$8.72M Sell
62,193
-72,463
-54% -$9.84M 0.09% 198
2017
Q2 		$16.6M Sell
134,656
-15,663
-10% -$1.82M 0.16% 184
2017
Q1 		$18.2M Sell
150,319
-1,466
-1% -$189K 0.17% 177
2016
Q4 		$18.6M Sell
151,785
-5,370
-3% -$657K 0.16% 172
2016
Q3 		$19.3M Buy
157,155
+6,848
+5% +$881K 0.17% 164
2016
Q2 		$17.8M Sell
150,307
-2,838
-2% -$403K 0.16% 168
2016
Q1 		$21.3M Buy
153,145
+2,194
+1% +$322K 0.19% 166
2015
Q4 		$28.8M Buy
150,951
+379
+0.3% +$66.2K 0.25% 132
2015
Q3 		$23.5M Sell
150,572
-2,443
-2% -$446K 0.21% 142
2015
Q2 		$27.7M Buy
153,015
+1,003
+0.7% +$173K 0.21% 141
2015
Q1 		$26.3M Sell
152,012
-48,843
-24% -$8.84M 0.2% 145
2014
Q4 		$37.2M Buy
200,855
+4,131
+2% +$765K 0.27% 131
2014
Q3 		$32.6M Sell
196,724
-2,584
-1% -$424K 0.25% 140
2014
Q2 		$31.1M Buy
+199,308
New +$31.5M 0.22% 163

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtus Fund Advisers's ALXN Position: Q4 2017 in Review

Virtus Fund Advisers increased its Alexion Pharmaceuticals (ALXN) stake by 11% in Q4 2017, buying an estimated $805K and bringing the position to 68,801 shares worth $8.23M. The position accounts for 0.08% of the portfolio, ranked #197.

Virtus Fund Advisers first reported a position in ALXN in Q2 2014 and has held it in 15 quarters since. The position peaked at $37.2M in Q4 2014. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Virtus Fund Advisers held 68,801 shares of Alexion Pharmaceuticals worth $8.23M as of Q4 2017.
  • Virtus Fund Advisers bought 6,608 Alexion Pharmaceuticals shares in Q4 2017, an estimated $805K.
  • Alexion Pharmaceuticals made up 0.08% of Virtus Fund Advisers's portfolio in Q4 2017, its #197 holding.
  • Virtus Fund Advisers first reported a position in Alexion Pharmaceuticals in Q2 2014 and has held it in 15 quarters since.
  • Virtus Fund Advisers's Alexion Pharmaceuticals position peaked at $37.2M in Q4 2014.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.